Histone lysine demethylase inhibition is a disease-modifying therapy for hypertrophic cardiomyopathy
Rationale: Hypertrophic cardiomyopathy (HCM) is a common inherited cardiac disorder characterized by cardiac hypertrophy, fibrosis, arrhythmias, and sudden cardiac death (SCD). Although current therapies primarily target sarcomere dysfunction, the contribution of epigenetic dysregulation to HCM pathogenesis and its therapeutic potential remain poorly understood. Objective: To determine whether…
We haven't written up this one. bioRxiv has the full story — the link below goes straight to it.
